|Day Low/High||47.00 / 49.00|
|52 Wk Low/High||14.75 / 50.85|
Savient to Seek Court Approval of Final Cash Collateral Order on December 13, 2013
Court Grants Orders to Support Business Operations
Enters into "Stalking Horse" Sale Agreement with US WorldMeds, LLC
Investors in Savient Pharmaceuticals Inc saw new options become available this week, for the November 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SVNT options chain for the new November 16th contracts and identified the following put contract of particular interest.
These under-$10 stocks look poised to trade higher from current levels.
Henry Schwartz of Trade Alert identified five stocks seeing bullish options activity.
Investors in Savient Pharmaceuticals Inc saw new options begin trading today, for the July expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SVNT options chain for the new July contracts and identified the following put contract of particular interest.
- First approved therapy in the European Union to address a significant unmet medical need for patients with chronic tophaceous gout
Rising short-interest indicates bearishness for the company is building up by investors. Between November 30 2012 and December 14, short-selling [...]
If Granted a Marketing Authorization, KRYSTEXXA Will Address a Significant Unmet Need for Certain Patients with Refractory Chronic Gout in the European Union
The biotech bubble grew in the third quarter, resulting in outsized gains for some unworthy stocks
Traders savvy enough to follow the low-priced names and trade them with discipline and sound risk management are banking ridiculous coin on a regular basis.
These stocks look ready to break out and trade higher from current levels.
Savient Pharmaceuticals' CEO Discusses Q2 2012 Results - Earnings Call Transcript
Results Published in The Journal of Rheumatology
Raises $44 Million in Net Proceeds and Extends Maturity on Significant Portion of its Debt
Hedge fund rips into Savient management and demands company liquidate remaining assets.
Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.
Investors have heavily discounted these high-quality companies.
Savient Pharmaceuticals (Nasdaq:SVNT) hit a new 52-week low Friday as it is currently trading at $1.89, below its previous 52-week low of $1.92 with 735,750 shares traded as of 12:20 p.m. ET. Average volume has been 1.6 million shares over the past 30 days.
Savient Pharmaceuticals (Nasdaq:SVNT) hit a new 52-week low Tuesday as it is currently trading at $2.02, below its previous 52-week low of $2.04 with 391,443 shares traded as of 10:45 a.m. ET. Average volume has been 1.6 million shares over the past 30 days.